Fukumoto Pharmaceutical: FY103 injection approved for clinical trials.

Fuyuan Pharmaceuticals Announcement: Recently, the company received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for FY103 injection, and will soon initiate clinical trials. FY103 injection is a first-class innovative drug independently developed by the company, which is used for the treatment of hypertension. The administration route is subcutaneous injection. Currently, there are no similar products approved for market in China or abroad with the same target. Up to now, the accumulated research and development investment for FY103 injection project is approximately RMB 29.49 million.